Skip to main content
SMMT logo

Summit Therapeutics Inc.

SMMTNASDAQHealthcareBiotechnology

$14.63Today:- (-)1Y −26.77%

As of Oct 16, 2026 close

Market cap
$11.96B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$12.07$29.23
Volume (live)
-
Avg. volume (3M)
6.83M

Summit Therapeutics (SMMT) Financial Ratios

For fiscal 2025 (fiscal year ended Dec 31, 2025), Summit Therapeutics had return on equity of -206.1% (down from -94.9%), debt-to-equity of 0.03 (up from 0.02), a current ratio of 9.87 (down from 10.15) and return on assets of -115.3% (down from -41.3%). A current ratio of 9.87 means current assets exceed current liabilities.

Summit Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio---1272.24145.30449.56
P/B Ratio20.4733.8523.547.083.164.87
Price/Tangible Book20.5334.0224.137.183.715.87
Enterprise Value Ratios
EV/Revenue---1105.42101.96425.46
Profitability & Returns
Return on Equity (ROE)-206.10%-94.89%-601.85%-75.05%-108.89%-66.57%
Return on Assets (ROA)-115.28%-41.30%-12.79%-10.23%-49.91%-32.91%
Return on Capital Employed (ROCE)-161.40%-53.60%-48.60%-10.20%-98.20%-63.40%
Leverage & Solvency Ratios
Debt/Equity0.030.021.374.100.030.01
Liquidity Ratios
Current Ratio9.8710.159.3016.933.804.41
Quick Ratio9.789.889.179.153.473.85
Efficiency Ratios
Asset Turnover---0.000.020.01
Yield & Distribution Ratios
Earnings Yield-8.00%-1.68%-33.62%-8.78%-33.71%-13.63%
FCF Yield-2.40%-1.08%-4.20%-4.71%-27.73%-12.55%
Buyback Yield-4.06%-15.96%-220.50%-109.60%-32.67%-111.78%

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Summit Therapeutics Financial Ratios

What is Summit Therapeutics's return on equity?

Summit Therapeutics's return on equity (ROE) was -206.1% for fiscal 2025 (period ended Dec 31, 2025). It was -94.9% a year earlier.

What is Summit Therapeutics's debt-to-equity ratio?

Summit Therapeutics's debt-to-equity ratio was 0.03 for fiscal 2025 (period ended Dec 31, 2025). It was 0.02 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition